E L Mayer1, V Abramson2, R Jankowitz3, C Falkson4, P K Marcom5, T Traina6, L Carey7, M Rimawi8, J Specht9, K Miller10, V Stearns11, N Tung12, C Perou7, A L Richardson11, K Componeschi13, L Trippa13, Z Tan-Wasielewski13, K Timms14, I Krop13, A C Wolff11, E P Winer13. 1. Dana-Farber Cancer Institute, Boston, USA. Electronic address: Erica_Mayer@dfci.harvard.edu. 2. Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, USA. 3. University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, USA. 4. University of Rochester Medical Center, Rochester, USA. 5. Duke University Cancer Institute, Durham, USA. 6. Memorial Sloan Kettering Cancer Center, New York, USA. 7. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, USA. 8. Baylor College of Medicine, Houston, USA. 9. Seattle Cancer Care Alliance, Seattle, USA. 10. Indiana University Simon Cancer Center, Indianapolis, USA. 11. Johns Hopkins University Sidney Kimmel Cancer Center, Baltimore, USA. 12. Beth Israel Deaconess Medical Center, Boston, USA. 13. Dana-Farber Cancer Institute, Boston, USA. 14. Myriad Genetics Inc., Salt Lake City, USA.
Abstract
BACKGROUND: Cisplatin and paclitaxel are active in triple-negative breast cancer (TNBC). Despite different mechanisms of action, effective predictive biomarkers to preferentially inform drug selection have not been identified. The homologous recombination deficiency (HRD) assay (Myriad Genetics, Inc.) detects impaired double-strand DNA break repair and may identify patients with BRCA1/2-proficient tumors that are sensitive to DNA-targeting therapy. The primary objective of TBCRC 030 was to detect an association of HRD with pathologic response [residual cancer burden (RCB)-0/1] to single-agent cisplatin or paclitaxel. PATIENTS AND METHODS: This prospective phase II study enrolled patients with germline BRCA1/2 wild-type/unknown stage I-III TNBC in a 12-week randomized study of preoperative cisplatin or paclitaxel. The HRD assay was carried out on baseline tissue; positive HRD was defined as a score ≥33. Crossover to an alternative chemotherapy was offered if there was inadequate response. RESULTS: One hundred and thirty-nine patients were evaluable for response, including 88 (63.3%) who had surgery at 12 weeks and 51 (36.7%) who crossed over to an alternative provider-selected preoperative chemotherapy regimen due to inadequate clinical response. HRD results were available for 104 tumors (74.8%) and 74 (71.1%) were HRD positive. The RCB-0/1 rate was 26.4% with cisplatin and 22.3% with paclitaxel. No significant association was observed between HRD score and RCB response to either cisplatin [odds ratio (OR) for RCB-0/1 if HRD positive 2.22 (95% CI: 0.39-23.68)] or paclitaxel [OR for RCB-0/1 if HRD positive 0.90 (95% CI: 0.19-4.95)]. There was no evidence of an interaction between HRD and pathologic response to chemotherapy. CONCLUSIONS: In this prospective preoperative trial in TNBC, HRD was not predictive of pathologic response. Tumors were similarly responsive to preoperative paclitaxel or cisplatin chemotherapy.
BACKGROUND: Cisplatin and paclitaxel are active in triple-negative breast cancer (TNBC). Despite different mechanisms of action, effective predictive biomarkers to preferentially inform drug selection have not been identified. The homologous recombination deficiency (HRD) assay (Myriad Genetics, Inc.) detects impaired double-strand DNA break repair and may identify patients with BRCA1/2-proficient tumors that are sensitive to DNA-targeting therapy. The primary objective of TBCRC 030 was to detect an association of HRD with pathologic response [residual cancer burden (RCB)-0/1] to single-agent cisplatin or paclitaxel. PATIENTS AND METHODS: This prospective phase II study enrolled patients with germline BRCA1/2 wild-type/unknown stage I-III TNBC in a 12-week randomized study of preoperative cisplatin or paclitaxel. The HRD assay was carried out on baseline tissue; positive HRD was defined as a score ≥33. Crossover to an alternative chemotherapy was offered if there was inadequate response. RESULTS: One hundred and thirty-nine patients were evaluable for response, including 88 (63.3%) who had surgery at 12 weeks and 51 (36.7%) who crossed over to an alternative provider-selected preoperative chemotherapy regimen due to inadequate clinical response. HRD results were available for 104 tumors (74.8%) and 74 (71.1%) were HRD positive. The RCB-0/1 rate was 26.4% with cisplatin and 22.3% with paclitaxel. No significant association was observed between HRD score and RCB response to either cisplatin [odds ratio (OR) for RCB-0/1 if HRD positive 2.22 (95% CI: 0.39-23.68)] or paclitaxel [OR for RCB-0/1 if HRD positive 0.90 (95% CI: 0.19-4.95)]. There was no evidence of an interaction between HRD and pathologic response to chemotherapy. CONCLUSIONS: In this prospective preoperative trial in TNBC, HRD was not predictive of pathologic response. Tumors were similarly responsive to preoperative paclitaxel or cisplatin chemotherapy.
Authors: Melinda L Telli; Jessica Hellyer; William Audeh; Kristin C Jensen; Shikha Bose; Kirsten M Timms; Alexander Gutin; Victor Abkevich; Rebecca N Peterson; Chris Neff; Elisha Hughes; Zaina Sangale; Joshua Jones; Anne-Renee Hartman; Pei-Jen Chang; Shaveta Vinayak; Richard Wenstrup; James M Ford Journal: Breast Cancer Res Treat Date: 2017-12-23 Impact factor: 4.872
Authors: Gunter von Minckwitz; Andreas Schneeweiss; Sibylle Loibl; Christoph Salat; Carsten Denkert; Mahdi Rezai; Jens U Blohmer; Christian Jackisch; Stefan Paepke; Bernd Gerber; Dirk M Zahm; Sherko Kümmel; Holger Eidtmann; Peter Klare; Jens Huober; Serban Costa; Hans Tesch; Claus Hanusch; Jörn Hilfrich; Fariba Khandan; Peter A Fasching; Bruno V Sinn; Knut Engels; Keyur Mehta; Valentina Nekljudova; Michael Untch Journal: Lancet Oncol Date: 2014-04-30 Impact factor: 41.316
Authors: Mansoor R Mirza; Bradley J Monk; Jørn Herrstedt; Amit M Oza; Sven Mahner; Andrés Redondo; Michel Fabbro; Jonathan A Ledermann; Domenica Lorusso; Ignace Vergote; Noa E Ben-Baruch; Christian Marth; Radosław Mądry; René D Christensen; Jonathan S Berek; Anne Dørum; Anna V Tinker; Andreas du Bois; Antonio González-Martín; Philippe Follana; Benedict Benigno; Per Rosenberg; Lucy Gilbert; Bobbie J Rimel; Joseph Buscema; John P Balser; Shefali Agarwal; Ursula A Matulonis Journal: N Engl J Med Date: 2016-10-07 Impact factor: 91.245
Authors: Nadine Tung; Banu Arun; Michele R Hacker; Erin Hofstatter; Deborah L Toppmeyer; Steven J Isakoff; Virginia Borges; Robert D Legare; Claudine Isaacs; Antonio C Wolff; Paul Kelly Marcom; Erica L Mayer; Paulina B Lange; Andrew J Goss; Colby Jenkins; Ian E Krop; Eric P Winer; Stuart J Schnitt; Judy E Garber Journal: J Clin Oncol Date: 2020-02-25 Impact factor: 44.544
Authors: William M Sikov; Donald A Berry; Charles M Perou; Baljit Singh; Constance T Cirrincione; Sara M Tolaney; Charles S Kuzma; Timothy J Pluard; George Somlo; Elisa R Port; Mehra Golshan; Jennifer R Bellon; Deborah Collyar; Olwen M Hahn; Lisa A Carey; Clifford A Hudis; Eric P Winer Journal: J Clin Oncol Date: 2014-08-04 Impact factor: 44.544
Authors: Cornelia Liedtke; Chafika Mazouni; Kenneth R Hess; Fabrice André; Attila Tordai; Jaime A Mejia; W Fraser Symmans; Ana M Gonzalez-Angulo; Bryan Hennessy; Marjorie Green; Massimo Cristofanilli; Gabriel N Hortobagyi; Lajos Pusztai Journal: J Clin Oncol Date: 2008-02-04 Impact factor: 44.544
Authors: Richard D Kennedy; Jennifer E Quinn; Paul B Mullan; Patrick G Johnston; D Paul Harkin Journal: J Natl Cancer Inst Date: 2004-11-17 Impact factor: 13.506
Authors: Ingrid A Mayer; Fengmin Zhao; Carlos L Arteaga; William F Symmans; Ben H Park; Brian L Burnette; Amye J Tevaarwerk; Sofia F Garcia; Karen L Smith; Della F Makower; Margaret Block; Kimberly A Morley; Chirag R Jani; Craig Mescher; Shabana J Dewani; Bernard Tawfik; Lisa E Flaum; Erica L Mayer; William M Sikov; Eve T Rodler; Lynne I Wagner; Angela M DeMichele; Joseph A Sparano; Antonio C Wolff; Kathy D Miller Journal: J Clin Oncol Date: 2021-06-06 Impact factor: 50.717
Authors: Milos Holanek; Iveta Selingerova; Ondrej Bilek; Tomas Kazda; Pavel Fabian; Lenka Foretova; Maria Zvarikova; Radka Obermannova; Ivana Kolouskova; Oldrich Coufal; Katarina Petrakova; Marek Svoboda; Alexandr Poprach Journal: Cancers (Basel) Date: 2021-03-30 Impact factor: 6.639